London’s Sava raises €32.08 million and partners with Ascensia to bring its glucose microsensor to Europe

What happened

Sava Technologies, a London-based HealthTech company developing a wearable biosensor platform that detects molecules just beneath the skin, today announced a $36 million Series B (an early stage of company funding) round to fund manufacturing scale-up and commercial readiness. The round was led by Ascensia, with participation from institutional investors Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments, Pentland Ventures and […] The post London’s Sava raises €32.08 million and partners with Ascensia to bring its glucose microsensor to Europe appeared first on EU-Startups .

In July 2025, the company announced a €16.6 million Series A funding round led by Balderton Capital and Pentland Ventures. In This funding brings the company’s total funding to $68 million.

The UK startup also announced an agreement appointing Ascensia, a subsidiary of PHC Holdings Corporation (TYO 6523), as its commercialisation and distribution partner, initially in Europe. After five years in stealth, it emerged in June 2024 and announced that it had raised more than €7.4 million in a Seed funding round led by Balderton Capital and Exor Ventures.

The round was led by Ascensia, with participation from institutional investors Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments, Pentland Ventures and others. Founded in 2019 by Imperial College London bioengineers Renato Circi and Rafaël Michali, Sava is a venture-backed consumer and medical device company behind a next-generation glucose microsensor.

Key facts

• In July 2025, the company — announced: a €16.6 million Series A funding round led by Balderton Capital and Pentland Ventures
• The UK startup also — announced: an agreement appointing Ascensia, a subsidiary of PHC Holdings Corporation (TYO 6523), as its commercialisation and distribution partner, initially in Europe